A study of somatic TERT promoter mutations in 302 patients with genitourinary tumors suggested that urothelial carcinoma had the highest TERT promoter mutation rates and no TERT promoter mutations were found in prostate cancer, which demonstrated TERT promoter mutation could be used as a target for the monitoring of recurrence and treatment of BC.32 The study of Li et al demonstrated that there was a high frequency of TERT promoter C228T mutation in bladder cancer stem cells (BCSCs). This evidence concerns the gene TERT and prostate cancer.